Janssen Biotech Simponi

Janssen Biotech has announced the FDA approval of Simponi (golimumab) to treat moderately to severely active ulcerative colitis (UC) in with corticosteroid dependence or an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, , or 6-.

The first and only subcutaneously administered anti- (TNF)-alpha therapy is approved to induce and maintain and improve endoscopic appearance of the during induction.

Additionally, the product is indicated to induce clinical and achieve and sustain clinical in induction responders.

A 200mg subcutaneous injection of Simponi should be administered at week zero, followed by 100mg at week two and then 100mg every four weeks, thereafter to treat UC.

Janssen Biotech announces FDA approval of Simponi ulcerative colitis therapy
Review
Janssen Biotech has announced the FDA approval of Simponi (golimumab) to treat moderately to severely active ulcerative colitis (UC) in adult patients with corticosteroid dependence or an inadequate response to or failed to tolerate oral

Janssen Biotech FDA approval Simponi Ulcerative Colitis

Leave a Reply